← All stocks

Allogene Therapeutics, Inc.

ALLO No buying or selling

CIK 0001737287 #2814 in the set updated 22 Sep 2026

Bought (1 mo)

$0.00

out of their own pocket, the only kind of buying there is

Sold (1 mo)

$0.00

$0.00 on a plan · $0.00 straight out of an exercise

Sold at will

$0.00

0 of 0 sales

Net

$0.00

$0.00 against sales at will

By person

11 insiders · 0 transactions

Insider

Role

Bought

Sold

Net

Holding

Worth

Change

Chang David D

President and CEO

—

5,150,599

$10.92M

+6.5%

Belldegrun Arie

Director

—

2,236,816

$4.74M

+19.8%

Parker Geoffrey M.

CHIEF FINANCIAL OFFICER

—

1,252,795

$2.66M

+6.1%

Roberts Zachary

President and CEO

—

581,166

$1.23M

+12.8%

Douglas Earl Martin

SVP, General Counsel

—

488,267

$1.04M

+21.4%

Kazam Joshua A

Director

—

398,463

$844.74K

+31.5%

Humer Franz B

Director

—

307,507

$651.91K

−2.9%

MOORE TIMOTHY L.

Chief Technical Officer

—

250,713

$531.51K

−5.6%

Beneski Benjamin Machinas

SVP, Chief Technical Officer

—

195,338

$414.12K

+1.6%

Yoshiyama Annie

SVP, Finance

—

124,517

$263.98K

+11.5%

MESSEMER DEBORAH M.

Director

—

107,431

$227.75K

−35.6%

No percentages here. These insiders hold more than one class of share between them, and the share count on file covers one of them rather than all. Dividing the two would compare different things.

Individual transactions

Nothing of that kind in this period.

What was left out

Form 4 filings counted 1

Amendments (4/A) skipped 0

Filings about a different issuer 0

Unreadable filings 0

Joint filings 0

Sales on a Rule 10b5-1 plan 0

Sales straight out of an exercise 0

Sales at will 0

Transactions with no price 0

Shares from compensation/vesting 0

History held since 17 Oct 2018